Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of parenteral nutrition on blood rheology and platelet aggregation in vitro.

Biorheology·2014
Same author

Fatigue in multiple sclerosis is not due to sleep apnoea.

European journal of neurology·2013
Same author

Cocaine in high concentrations inhibits platelet aggregation in vitro.

Clinical hemorheology and microcirculation·2013
Same author

The passage of a hemodialysis filter affects hemorheology, red cell shape, and platelet aggregation.

Clinical hemorheology and microcirculation·2013
Same author

[Histoplasmosis - an unusual African souvenir].

Deutsche medizinische Wochenschrift (1946)·2013
Same author

Studies on metabolically depleted erythrocytes.

Clinical hemorheology and microcirculation·2013

Related Experiment Video

Updated: May 18, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Platelets in vascular disease.

W H Reinhart1

  • 1Department of Internal Medicine, Kantonsspital Graubünden, Chur, Switzerland. walter.reinhart@ksgr.ch

Clinical Hemorheology and Microcirculation
|September 8, 2012
PubMed
Summary
This summary is machine-generated.

Platelet aggregation is crucial in vascular diseases. Current treatments like aspirin and clopidogrel inhibit this, but new drugs aim for better efficacy and safety.

More Related Videos

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
11:18

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Related Experiment Videos

Last Updated: May 18, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
11:18

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Area of Science:

  • Cardiovascular Science
  • Hematology
  • Pharmacology

Background:

  • Platelets are vital for hemostasis and implicated in atherosclerosis, stroke, and myocardial infarction.
  • Plaque rupture triggers platelet adhesion, activation, and aggregation, potentially causing vascular occlusion.
  • Hemorheological factors significantly influence platelet-driven thrombotic processes.

Purpose of the Study:

  • To explore the role of platelets in atherothrombosis.
  • To review current antiplatelet therapies and their mechanisms.
  • To discuss the development of novel antiplatelet agents balancing efficacy and bleeding risk.

Main Methods:

  • Review of existing literature on platelet function and antiplatelet therapies.
  • Analysis of mechanisms underlying platelet activation and aggregation.
  • Examination of pharmacological approaches to inhibit platelet activity.

Main Results:

  • Platelet aggregation is a central mechanism in atherothrombotic events.
  • Acetylsalicylic acid and clopidogrel are established treatments inhibiting platelet aggregation.
  • Challenges remain in developing agents with improved efficacy and reduced bleeding complications.

Conclusions:

  • Platelet inhibition is fundamental in managing vascular diseases.
  • Current antiplatelet drugs target thromboxane and ADP pathways.
  • Future research focuses on developing more effective and safer antiplatelet strategies.